Analyst Ratings for [GKOS] Glaukos Corporation

10/1/25	Initiated	Buy	X
GKOS Glaukos Goldman
$103
5/1/25	Downgrades	Overweight Eq Weight	X
GKOS Glaukos Wells Fargo
$86
2/19/25	Upgrades	Neutral Outperform	X
GKOS Glaukos Mizuho
$140 $200
12/11/24	Upgrades	Neutral Buy	X
GKOS Glaukos Citigroup
$132 $162
12/6/24	Initiated	Buy	X
GKOS Glaukos UBS
$182
12/2/24	Downgrades	Eq-Weight Underweight	X
GKOS Glaukos Morgan Stanley
$120
7/10/24	Downgrades	Buy Neutral	X
GKOS Glaukos Citigroup
$132
12/21/23	Upgrades	Neutral Overweight	X
GKOS Glaukos JP Morgan
$66 $91
12/4/23	Initiated	Equal-Weight	X
GKOS Glaukos Morgan Stanley
$65
11/28/23	Initiated	Buy	X
GKOS Glaukos Truist
$88
6/7/23	Upgrades	Neutral Overweight	X
GKOS Glaukos Piper Sandler
$55 $80
12/22/22	Initiated	Neutral	X
GKOS Glaukos Mizuho
$48
12/19/22	Upgrades	Underweight Neutral	X
GKOS Glaukos JP Morgan
$48 $42
12/12/22	Upgrades	Neutral Buy	X
GKOS Glaukos Citigroup
$57
10/14/22	Resumed	Overweight	X
GKOS Glaukos Stephens
$69
10/4/22	Initiated	Buy	X
GKOS Glaukos Needham
$66
7/12/22	Upgrades	Hold Buy	X
GKOS Glaukos Stifel
$40 $60
2/3/22	Upgrades	Mkt Perform Outperform	X
GKOS Glaukos William Blair
1/19/22	Upgrades	Underweight Eq Weight	X
GKOS Glaukos Wells Fargo
$56
1/18/22	Upgrades	Neutral Buy	X
GKOS Glaukos BTIG Research
$61
11/3/21	Upgrades	Eq-Weight Overweight	X
GKOS Glaukos Stephens
$68
7/26/21	Downgrades	Overweight Eq-Weight	X
GKOS Glaukos Stephens
$70
7/20/21	Downgrades	Eq Weight Underweight	X
GKOS Glaukos Wells Fargo
$41
7/14/21	Downgrades	Outperform Perform	X
GKOS Glaukos Oppenheimer
7/14/21	Downgrades	Outperform Mkt Perform	X
GKOS Glaukos William Blair
4/8/21	Upgrades	Perform Outperform	X
GKOS Glaukos Oppenheimer
$100
1/29/21	Downgrades	Overweight Neutral	X
GKOS Glaukos Piper Sandler
$70 $80
3/8/19	Initiated	Neutral	X
GKOS Glaukos BTIG Research
8/30/18	Initiated	Hold	X
GKOS Glaukos Berenberg
$57
8/3/18	Reiterated	Hold	X
GKOS Glaukos Stifel
$32 $35
6/21/18	Downgrades	Overweight Neutral	X
GKOS Glaukos JP Morgan
4/13/18	Downgrades	Buy Hold	X
GKOS Glaukos Stifel
$39 $32
3/1/18	Reiterated	Buy	X
GKOS Glaukos Cantor Fitzgerald
$48 $43

GKOS Glaukos Corporation

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.